Immunotherapy can accentuate the effect created by SABR alone via checkpoint inhibition (PD-1 and CTLA4) or targeting other immune pathways such as GITR (glucocorticoid-induced tumour necrosis factor-related protein acts as a co-stimulatory receptor), promoting anti-tumour responses [102]. Here, CTLA4 is linked to neoplasm.